Skip to content

H Bottemanne

Paris Brain Institute - Institut du cerveau (ICM), Sorbonne University/CNRS/Inserm, UMR 7225/UMRS 1127, Paris, France; Sorbonne University, Department of Philosophy, UMR 8011, CNRS, Paris, France; Department of Psychiatry, Pitié-Salpêtrière Hospital, DMU Neuroscience, Sorbonne University, AP-HP, Paris, France. Electronic address: hugo.bottemanne@aphp.fr.

1 paper in the library · 7 citations · publishing 2022

Papers

[Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide].

L'Encephale June 1, 2022 H Bottemanne, A Baldacci, C Muller et al. 7 citations

Ketamine, a fast-acting antidepressant, produces dissociative effects and promotes brain plasticity. Although preliminary studies suggest combining it with psychotherapy may be beneficial, clinical antidepressant use rarely includes per- and post-infusion therapy. The psychodysleptic experiences and synaptogenic effects could enhance cognitive behavioral therapy. This article proposes a practical protocol for Ketamine Augmented Psychotherapy (KAP), synthesizing literature and clinical experience. It details four steps: preparation, administration, integration, and prolongation, and discusses limits and prospects for mood disorder management.